Nektar Therapeutics

Yahoo Finance • 22 days ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Key Points Shares of Nektar Therapeutics and Mineralys Therapeutics have risen sharply, and could run even further. Nektar is developing an experimental eczema treatment. Millions of patients with stubbornly high blood pressure could bene... Full story

Yahoo Finance • 3 months ago

Why Nektar Therapeutics Stock Dived by 3% Today

Key Points The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. Nektar Therapeutics(NASDAQ: NKTR) saw its stock price erode on Thursday, following the... Full story

Yahoo Finance • 3 months ago

Top Midday Decliners

Nektar Therapeutics (NKTR) slid 4.5% on Thursday after the biopharmaceuticals firm overnight said it PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Nektar Therapeutics stock dips after pricing $100M stock offering

* Nektar Therapeutics (NASDAQ:NKTR [https://seekingalpha.com/symbol/NKTR]) shares slipped over 3% premarket on Tuesday after the biotechnology company priced a stock offering to raise around $100M. * Nektar is selling 4.25M shares of c... Full story

Yahoo Finance • 4 months ago

Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings

[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 4 months ago

Nektar Therapeutics surge continues as stock up another 25%

[graph from neons 1] Jonathan Kitchen * Nektar Therapeutics (NASDAQ:NKTR [https://seekingalpha.com/symbol/NKTR]), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic d... Full story

Yahoo Finance • 4 months ago

Nvidia and Tesla Stir Mega-Cap Movers on Wednesday's Market

Wednesday’s market has seen notable fluctuations among stocks, with significant movements in both the mega-cap and large-cap categories. Nvidia Corp (NASDAQ:NVDA) has experienced a surge, while Tesla Motors (NASDAQ:TSLA) has dipped. Ot... Full story

Yahoo Finance • 4 months ago

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2... Full story

Yahoo Finance • 4 months ago

Nektar stock price target raised to $69 from $2 at Jefferies on AD data

Investing.com - Jefferies raised its price target on Nektar Therapeutics (NASDAQ:NKTR) to $69.00 from $2.00 on Tuesday, maintaining a Buy rating following positive Phase 2b atopic dermatitis (AD) data for the company’s Rezpeg treatment.... Full story

Yahoo Finance • 4 months ago

Nektar stock price target raised to $100 from $60 at BTIG on trial data

Investing.com - BTIG raised its price target on Nektar Therapeutics (NASDAQ:NKTR) to $100 from $60 while maintaining a Buy rating following positive Phase 2b trial results for the company’s atopic dermatitis treatment. The research firm... Full story

Yahoo Finance • 4 months ago

Nektar's rezpegaldesleukin shows positive results in atopic dermatitis trial

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotechnology company with a market capitalization of $118 million, announced Tuesday that its Phase 2b REZOLVE-AD study of rezpegaldesleukin met its primary endpoint in patients with mo... Full story

Yahoo Finance • 4 months ago

Nektar Therapeutics stock soars on upcoming atopic dermatitis data

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic dermatitis treatment in June 2025. The cl... Full story

Yahoo Finance • 7 months ago

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling b... Full story

Yahoo Finance • 7 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference:(... Full story

Yahoo Finance • last year

Nektar Therapeutics' (NASDAQ:NKTR) large institutional owners must be happy as stock continues to impress, up 13% over the past week

Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions The top 19 shareholders own 50% of the company Recent sales by insiders If you want to know who really... Full story

Yahoo Finance • 2 years ago

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time. (... Full story

Yahoo Finance • 2 years ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial m... Full story

Yahoo Finance • 2 years ago

Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners

Key Insights Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable to their trading decisions The top 11 shareholders own 51% of the company Recent sales by insiders If you want to know... Full story

Yahoo Finance • 3 years ago

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to... Full story

Yahoo Finance • 3 years ago

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-based financial markets. Howard Robin, Pre... Full story